

	PRIMARY CARE CLINICAL DIGEST MAY 3 2024
What's in this issue?	<ol style="list-style-type: none"> 1. Workforce development funding for Primary and Community Care 2. Survey on issues with GP2GP 3. 2024 Influenza Campaign 4. Changes to Eltroxon (levothyroxine) 5. Outbreak of dengue fever in Samoa 6. Seeking EOIs to fill a vacancy on the National Palliative Care Steering Group 7. Medicinal cannabis products that meet the minimum quality standard: Medleaf Orange Kush C 8. Webinar reminder: Simplifying HIV prevention: updates for prescribing PrEP and PEP 9. Tender notification: Dasatinib 10. Building the future of health virtual hui May 7 2024 11. Pharmac notification: April Tender 12. Updates on supply issues May 3 2024 13. Top Weekend Viewing
Workforce development funding for Primary and Community Care	<p>Te Whatu Ora launches funding to boost workforce development for Primary and Community Care</p> <ul style="list-style-type: none"> • The interim New Zealand Health Plan, Te Pae Tata, identifies that strengthening primary and community care helps reduce the risk and burden of disease, reduces demand for more costly and intensive specialist care, and ultimately achieves better and more equitable health and wellbeing outcomes for New Zealanders. • Te Whatu Ora is introducing new funding to support the development of the primary and community health workforce. The new funding will focus on further education and skills development for health workers in the primary and community care workforce (i.e. employed by PHOs, GP practices, Hauora Māori and Pacific community providers, or aged care providers). • Te Pae Tata also requires action with a strong focus on improving equity and access to primary health care. Research shows that expanding the skill mix available to primary care teams increases community access and improves equity outcomes. Comprehensive primary care teams within local provider networks support this and have a priority focus on Māori, Pacific, and rural people. • Further information on the funding and eligibility criteria is available on the website and the Health New Zealand website has more information and how to apply for this funding.
Survey on issues with GP2GP	<ul style="list-style-type: none"> • A working group has formed between Te Whatu Ora Data & Digital and GPNZ to work on the issues being experienced with GP2GP. This is supported by clinicians and practice

	<p>managers who are providing expert advice as part of the wider project team.</p> <ul style="list-style-type: none"> • High level problem statements have been articulated to highlight the clinical risk and administrative burden felt in practices from GP2GP. We now need to build a deeper understanding on issues and incidence rates. • We invite practice managers to please contribute to our discovery by filling in this short survey, which should take no more than ten minutes.
<p>2024 Influenza Campaign</p>	<p>Vaccinating Health Worker</p> <ul style="list-style-type: none"> • For all information related to the Vaccinating Health Worker role, training and authorisation requirements, a number of resources are available online: <ul style="list-style-type: none"> ○ Vaccinating Health Worker Guide ○ Becoming a Vaccinating Health Worker ○ Information for Vaccinating Health Worker Clinical Supervisors ○ Information for Employers ○ Information for Employers new to the Vaccinating Health Worker role • The above collateral is located on the Health New Zealand Te Whatu Ora Vaccinating Workforce webpage, which has a lot of useful information for all vaccinators. • A free, online course is also available for Clinical Supervisors of VHW. You can access this through the IMAC website. Note: all training for and related to the VHW role is free. <p>Second checker</p> <ul style="list-style-type: none"> • The Second Checker course is for non-registered team members such as kaiāwhina, health care assistants, administration staff, pharmacy technicians and retail assistants to enable them to complete specific checks of the vaccine preparation process in settings where there is limited clinical staff onsite. Anyone can complete the course as it's a useful refresher for all vaccinators. • The online course is free and available on the IMAC website.
<p>Changes to Eltroxin (levothyroxine)</p>	<ul style="list-style-type: none"> • Aspen NZ, the supplier of Eltroxin (levothyroxine), has informed Pharmac that the 50 mcg and 100 mcg tablets are changing and have provided some materials to prepare you, and people who take Eltroxin, for this change. <ul style="list-style-type: none"> ○ Eltroxin health care professional letter ○ Eltroxin Tablet Guide for health care professionals ○ Your Eltroxin® is changing (Thyroid Medication) - patient flyer • The new Eltroxin tablets will have the same active and excipient ingredients. The manufacturing site for this medicine will also remain the same. • These are small product changes and will align the Eltroxin product available in New Zealand with the Eltroxin product available in Australia. Medsafe has reviewed these changes

	<p>to ensure the product meets standards of quality, safety, and efficacy.</p> <ul style="list-style-type: none"> • The Eltroxin tablet changes are likely to happen as the current tablet supply runs out. • Please refer to the Medsafe Eltroxin data sheet for all prescribing information and Schedule listing for levothyroxine • For Eltroxin medical information enquiries, please email the Aspen Medical Information Department on medical@aspenpharmacare.com.au. • To contact the Aspen New Zealand Head Office, please call 09 220 5399 or 0800 858 377 or via email at aspen@aspenpharma.co.nz.
<p>Outbreak of dengue fever in Samoa See attached factsheets (English and Samoan language)</p>	<ul style="list-style-type: none"> • There is currently a significant outbreak of dengue fever in Samoa. Please remain vigilant for recent travellers who may present with symptoms. For those who have patients who may be travelling to Samoa, the attached advice is also available to share. • Dengue fever is not spread from person to person. A person becomes infected with the dengue virus after being bitten by an infected mosquito. • Symptoms, treatment, prevention and more information can be found in the attached fact sheet. <p>Management of dengue fever</p> <ul style="list-style-type: none"> • Please follow HealthPathways advice for Fever in Returning Travellers. • Laboratory testing involves full blood count (leucopenia, thrombocytopenia, elevated ALT, increased HCT), and testing for the dengue virus (PCR) or antigen and/or serology tests. • Treatment is supportive, but NSAIDS (ibuprofen/aspirin) should be avoided. Seek infectious diseases advice if concerned, including if your patient has previously had dengue or there are any signs of bleeding. • Public health management: no isolation is required. Notification should be made to the local medical officer of health on suspicion. <p>Advice for patients travelling to Samoa</p> <ul style="list-style-type: none"> • Please advise travellers to Samoa to protect themselves from mosquito bites when they are in Samoa, and to contact their GP or Healthline if they develop a fever or other symptoms after their return to New Zealand. • If travellers develop symptoms while in Samoa, they may need to seek healthcare locally. • Encourage them to check the latest public health advice – further information about dengue is available here and guidance on how to stay healthy when travelling is available here. • Additional safe travel advice for those travelling to Samoa can be found here.

<p>Seeking EOIs to fill a vacancy on the National Palliative Care Steering Group See attached EOI form and TORs</p>	<ul style="list-style-type: none"> • See attached information to apply for the paediatric services vacancy or email stephanie.read@tewhatuora.govt.nz • Applications close on May 15 2024 and to be sent to palliativecare@tewhatuora.govt.nz.
<p>Medicinal cannabis products that meet the minimum quality standard: Medleaf Orange Kush C View online</p>	<ul style="list-style-type: none"> • Information on this topic can be viewed via the online link.
<p>Webinar reminder: Simplifying HIV prevention: updates for prescribing PrEP and PEP</p>	<ul style="list-style-type: none"> • A reminder you can register for this webinar being held Tuesday May 14 2024 from 7.00pm to 8.00pm here Webinar Registration - Zoom
<p>Tender notification: Dasatinib View online</p>	<ul style="list-style-type: none"> • Information on this tender notification can be found on the attached link.
<p>Building the future of health virtual hui May 7 2024 View online</p>	<ul style="list-style-type: none"> • Click on the attached link to register for this hui which is between 3.00pm – 3.45pm on May 7.
<p>Pharmac notification: April Tender View online</p>	<ul style="list-style-type: none"> • To view April 2024 Tender Notification, click on the attached link.
<p>Updates on supply issues May 3 2024 View online</p>	<ul style="list-style-type: none"> • See attached link to view the Pharmac updates.
<p>Top Weekend Viewing</p>	<ul style="list-style-type: none"> • This week, try some of these local comedy gems showing on ThreeNOW and all made with the support of NZ On Air. <ul style="list-style-type: none"> ○ Golden Boy - Follow the hilarious life of small-town girl Mitch as she lives in the constant shadow of her rugby star brother Tama. View trailer ○ New Zealand Today - Volunteer journalist Guy Williams visits small-town New Zealand to investigate what he thinks are the most interesting stories in New Zealand today. View trailer ○ Homebound 3.0 - A struggling 30-something unpublished writer is forced to move back home and deal with the disappointment of his Chinese parents. View trailer